InMed Pharmaceuticals Inc. (C:IN*CA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: SUITE 310, 815 W. HASTINGS STREET
VANCOUVER BC V6C 1B4
Tel: N/A
Website: https://www.inmedpharma.com
IR: See website
<
Key People
Eric A. Adams
President, Chief Executive Officer, Director
N. Netta Jagpal
Chief Financial Officer, Corporate Secretary
Michael Henry Woudenberg
Chief Operating Officer
Eric Chih-Hsien Hsu
Senior Vice President - Preclinical Research and Development
Alexandra D.J. Mancini
Senior Vice President - Clinical and Regulatory Affairs
 
Business Overview
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.
Financial Overview
For the six months ended 31 December 2023, InMed Pharmaceuticals Inc revenues increased from $791K to $2.1M. Net loss decreased 28% to $4M. Revenues reflect BayMedica segment increase from $470K to $2.1M. Lower net loss reflects General and administrative - Balancing v decrease of 11% to $2.4M (expense), Research and development and patents - B decrease of 12% to $1.9M (expense).
Employees: 13 as of Jun 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $5.49M as of Dec 31, 2023
EBITDA (TTM): -$6.78M as of Dec 31, 2023
Net annual income (TTM): -$6.35M as of Dec 31, 2023
Free cash flow (TTM): -$6.50M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 6,056,970 as of Feb 13, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.